Scarica l'app Stockscreener
1.28
12.93%
-0.19
Dopo l'orario di chiusura:
1.21
-0.07
-5.47%
Lexaria Bioscience Corp Borsa (LEXX) Ultime notizie
Lexaria Bioscience stock hits 52-week low at $1.37 By Investing.com - Investing.com South Africa
Lexaria Bioscience Advances Strategy in GLP-1 Drug Sector - TipRanks
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience - TradingView
Could This Small Biotech Solve GLP-1 Drugs' Biggest Problems? Lexaria's Triple Strategy Explained - StockTitan
Lexaria Bioscience Advances GLP-1 Study with New Ethics Approval - TipRanks
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm - TradingView
Can This Small Biotech Transform GLP-1 Drugs From Shots to Pills? Clinical Trial Update - StockTitan
Lexaria Bioscience Targets Breakthrough in Oral Diabetes Medication - TipRanks
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide - WICZ
Can This Small Biotech Revolutionize $30B GLP-1 Market With First-Ever Oral Liraglutide? - StockTitan
Lexaria Bioscience Corp. (NASDAQ:LEXX) Sees Significant Decline in Short Interest - Defense World
Lexaria Bioscience stock hits 52-week low at $1.62 - MSN
Lexaria Secures Two New Patents for Epilepsy Treatment with DehydraTECH - MSN
Lexaria secures new patents for epilepsy treatment tech By Investing.com - Investing.com Nigeria
Lexaria Bioscience stock hits 52-week low at $1.62 By Investing.com - Investing.com South Africa
Lexaria secures new patents for epilepsy treatment tech - MSN
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy - WICZ
Lexaria's Game-Changing Epilepsy Patents Outperform Epidiolex Technology | LEXX - StockTitan
Lexaria Initiates Groundbreaking Biodistribution Study for DehydraTECH GLP-1 - TipRanks
Revolutionary GLP-1 Study: Lexaria's DehydraTECH Goes Head-to-Head with Rybelsus - StockTitan
Lexaria Advances Human Study on Diabetes and Weight Loss Treatment - TipRanks
Revolutionary GLP-1 Breakthrough: Lexaria's Technology Matches Zepbound Efficacy with Fewer Side Effects - StockTitan
Lexaria reports promising drug delivery study results - Investing.com India
Research Analysts Issue Forecasts for LEXX Q2 Earnings - Defense World
Lexaria Bioscience Strengthens GLP-1 Drug Delivery Focus and Expands Patent Portfolio in 2024 - TipRanks
Lexaria Releases Annual Letter from the CEO - WICZ
GLP-1 Game-Changer: This Small Biotech Found How to Slash Semaglutide Side Effects by 60% - StockTitan
What is Zacks Small Cap’s Estimate for LEXX Q4 Earnings? - Defense World
LEXX: IRB Approval Clears Way for GLP-1 Study #5 - Yahoo Finance
HC Wainwright Has Lowered Expectations for Lexaria Bioscience (NASDAQ:LEXX) Stock Price - Defense World
Lexaria Bioscience stock target cut to $7 at H.C. Wainwright By Investing.com - Investing.com South Africa
Lexaria Bioscience stock target cut to $7 at H.C. Wainwright - Investing.com
Lexaria Bioscience Holds Successful Shareholder Meeting; Votes in New Directors and Approves Proposals - Defense World
Lexaria Bioscience shareholders approve board and auditor selections - Investing.com
Lexaria Bioscience Advances with Human Study for Oral Liraglutide - TipRanks
LEXXLexaria Bioscience Corp. Latest Stock News & Market Updates - StockTitan
Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval - WICZ
Lexaria Gets Green Light for Oral Weight Loss Drug Trial, Aims to Replace Saxenda Injections - StockTitan
Lexaria’s Oral Drug Shows Promising Results Against Eli Lilly’s Injection - TipRanks
Lexaria's Oral GLP-1 Drug Shows 47% Fewer Side Effects Than Injectable Zepbound in Clinical Study - StockTitan
Lexaria Bioscience First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Geode Capital Management LLC Increases Position in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World
Lexaria Bioscience Corp. Reports Earnings Results for the First Quarter Ended November 30, 2024 - Marketscreener.com
Lexaria Bioscience Earnings Analysis: Q1 Recap - Benzinga
Lexaria Bioscience Corp. (LEXX) reports earnings - Quartz
NRx Pharmaceuticals (NASDAQ:NRXP) and Lexaria Bioscience (NASDAQ:LEXX) Head to Head Contrast - Defense World
Lexaria Bioscience Announces Executive Management Agreement ChangesLexaria Bioscience Corp. (OTCMKTS:LXRP) recently disclosed key alterations to its Executive Management Agreement in a current report filed with the Securities and Exchange Com - Defense World
3.13%
1.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):